Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma

1 Mar 2020

Abstract excerpt

BACKGROUND: Current guidelines lack recommendations for the use of immunotherapy and immune-related biomarkers for hepatocellular carcinoma (HCC). We aim to provide reliable evidence of the association of survival with HCC immunotherapy and to demonstrate that genomic mutation signature could be an effective biomarker to predict immunotherapy efficacy of HCC patients. METHODS: We conducted a meta-analysis of 17...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32309377
DOI: 10.21037/atm.2020.01.32

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinomaPMID 32309377Read ↗

Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.Semantic proximity Read ↗

The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.Semantic proximity Read ↗

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.Semantic proximity Read ↗

Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.Semantic proximity Read ↗

Construction and validation of a novel signature based on epithelial-mesenchymal transition–related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironmentSemantic proximity Read ↗

Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis.Semantic proximity Read ↗

Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.Semantic proximity Read ↗

CTNNB1-mutation-related immune gene prognostic model (CMRIPM) for hepatocellular carcinoma: Development and validationSemantic proximity Read ↗

Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysisSemantic proximity Read ↗

Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinomaSemantic proximity Read ↗

Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis.Semantic proximity Read ↗

A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.